Day: March 14, 2022

Philips showcases connected, scalable health informatics solutions at HIMSS22

Written by Customer Service on March 14, 2022. Posted in Public Companies.

Patient Flow SolutionClinician at BedsidePerformanceBridgePatient wearing MCOT at homeMarch 14, 2022Flexible, secure, cloud-based Philips HealthSuite solutions and innovative business models aim to connect care across settings, address workforce challenges, drive efficiency and improve outcomes Informatics solutions provide deep insights at the points-of-care in acute, ambulatory, and interventional settings, and beyond to simplify care orchestration for providers and help improve patient outcomes and experienceAmsterdam, the Netherlands and Orlando, Florida, USA – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, will showcase its latest secure, connected and scalable informatics solutions during the HIMSS22 Global Health Conference & Exhibition. Philips will share its deep clinical and...

GreenLight Biosciences Holdings, PBC (GRNA) enters into multitarget licensing agreement with Serum Institute of India to develop and commercialize messenger RNA products for emerging markets globally

Written by Customer Service on March 14, 2022. Posted in Public Companies.

GreenLight test tubes Serum Institute of India (SII) is the world’s largest vaccine manufacturer by number of doses produced and sold.Serum Institute of India has engaged GreenLight to design three messenger RNA products, including a vaccine for shingles. Serum Institute of India also has an option to expand the relationship further for two additional vaccine or therapeutic targets.Serum Institute of India will receive a license to develop, manufacture, and commercialize the resulting products in a number of emerging markets, including Africa, Latin America, the Middle East, and much of Asia.GreenLight retains the right to develop, manufacture and commercialize those products in North America, Europe, Australia, New Zealand, China, Japan, and South Korea.GreenLight will make a technology transfer of its scalable and cost-effective...

AAR signs exclusive distribution agreement with Collins Aerospace’s Goodrich De-Icing & Specialty Heating Systems business

Written by Customer Service on March 14, 2022. Posted in Public Companies.

Wood Dale, Illinois, March 14, 2022 (GLOBE NEWSWIRE) — AAR (NYSE: AIR), a leading provider of aviation services to commercial and government operators, MROs, and OEMs, has signed an exclusive distribution agreement with Collins Aerospace’s Goodrich De-Icing & Specialty Heating Systems business. Through this agreement, AAR will provide airlines, other aircraft operators, and MROs globally with de-icers and supporting products. Product offerings include patented technology and are predominantly used on general aviation aircraft, regional turbo-prop aircraft, and most multi-engine piston business aircraft. “We are excited to distribute Collins’ De-Icing & Specialty Heating Systems and expand our portfolio and offerings, particularly to the business and general aviation marketplace,” said Eric Young, Vice President of OEM...

Genmab Announces the Nomination of a New Member of the Company’s Board of Directors

Written by Customer Service on March 14, 2022. Posted in Public Companies.

Company AnnouncementGenmab’s Board of Directors proposes that Elizabeth O’Farrell is elected as a new member of the Board of DirectorsCOPENHAGEN, Denmark; March 14, 2022 – Genmab A/S (Nasdaq: GMAB) announced today that the Company’s Board of Directors nominates Elizabeth O’Farrell for election as a new member of the Board of Directors at the Annual General Meeting, which will be held on March 29, 2022. The Board of Directors initiated a replacement process for a candidate to replace Jonathan Peacock who stepped down from the Board of Directors last year. Following a comprehensive process, the Board of Directors nominates Elizabeth O’Farrell for election to the Genmab Board of Directors for a one year period in addition to the nomination of the current members of the Board of Directors for re-election on agenda item 5 of the summons...

BBQ Holdings, Inc. Reports Results for Fourth Quarter and Fiscal Year 2021; Announces Acquisition of Barrio Queen, Corporate Name Change and Provides 2022 Guidance

Written by Customer Service on March 14, 2022. Posted in Earnings Releases And Operating Results.

MINNEAPOLIS, March 14, 2022 (GLOBE NEWSWIRE) — BBQ Holdings, Inc. (NASDAQ: BBQ) (the “Company”), an innovating global franchisor, owner and operator of restaurants, today reported financial results for the fourth quarter and fiscal year ended January 2, 2022. Fourth Quarter Highlights: Fourth Quarter(dollars in thousands, except per share data) 2021 2020 2019 Total revenue $ 68,395 $ 34,258 $ 23,613 Net income (loss) $ 2,602 $ (2,836 ) $ (1,788 ) Earnings (loss) per diluted share $ 0.25 $ (0.31 ) $ (0.20 ) Adjusted net income (loss) $ 2,820 $ (1,538 ) $ (1,210 ) Adjusted earnings (loss) per diluted share $ 0.27 $ (0.17 ) $ (0.13 ) Cash EBITDA $ 4,550 $ 85 $ (692 ) Restaurant-level...

Form 8.3 – [Clinigen Group plc – 11 03 2022] – (CGWL)

Written by Customer Service on March 14, 2022. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree CLINIGEN GROUP PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date position held/dealing undertaken: For...

Abcam Plc Results for the 12- and 18-month periods ended 31 December 2021

Written by Customer Service on March 14, 2022. Posted in Earnings Releases And Operating Results.

Growing demand for Abcam’s portfolio of in-house products drives calendar 2021 revenues up by 22% at constant exchange rates Acquisition of BioVision completed 26 October 2021 CAMBRIDGE, United Kingdom, March 14, 2022 (GLOBE NEWSWIRE) — Abcam plc (Nasdaq: ABCM; AIM: ABC) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, today announces its final results for the 18-month period ended 31 December 2021 (the ‘period’). The Group’s accounting reference date changed from 30 June to 31 December during the year1, therefore these financial statements report on both a 12- and 18-month period. SUMMARY PERFORMANCE£m, unless stated otherwise 12 months ended 31 Dec 2021 (unaudited)(‘CY2021’) 12 months ended 31 Dec 2020 (unaudited)(‘CY2020’) 18 months ended 31 Dec 2021 (audited)Revenue 315.4 269.3 462.9Adjusted...

Adaptimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update

Written by Customer Service on March 14, 2022. Posted in Earnings Releases And Operating Results.

– SPEARHEAD-1 met its primary endpoint – planning for afami-cel BLA submission in Q4 2022 for people with synovial sarcoma – – Moving to late-phase development with ADP-A2M4CD8: SURPASS-2 initiated in esophageal and EGJ cancers; initiating SURPASS-3 in ovarian cancer in 2022 – – Allogeneic platform on-track for planned IND submission in 2023 for first product targeting MAGE-A4 – – Started our strategic collaboration for allogeneic T-cell therapies with Genentech – $150 million upfront payment received – – Scaling up autologous patient supply at Navy Yard facility and construction underway of a dedicated allogeneic cell manufacturing facility in the UK – – Appointed Cintia Piccina as Chief Commercial Officer – – Financial guidance confirmed: funded...

F-star Therapeutics Reports Full-Year 2021 Financial Results and Provides Corporate Update

Written by Customer Service on March 14, 2022. Posted in Earnings Releases And Operating Results.

Multiple Clinical Program Updates Expected in 2022 Continued Expansion of Leading Bispecific Antibody IP Estate Two New Significant Partnerships with Janssen and AstraZeneca Company to Host Conference Call Today at 9 a.m. EDT CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) — F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced full-year 2021 financial results and will provide a corporate update. “Bispecifics have come of age, and F-star is exceptionally well positioned in this field with our unique tetravalent bispecific platform,” said Eliot Forster, Chief Executive Officer of F-star Therapeutics. “With all four of our clinical programs poised to...

Ideal Power Appoints Two Independent Members to its Board of Directors

Written by Customer Service on March 14, 2022. Posted in Public Companies.

AUSTIN, Texas, March 14, 2022 (GLOBE NEWSWIRE) — Ideal Power Inc. (Nasdaq: IPWR), pioneering the development and commercialization of highly efficient and broadly patented B-TRAN™ bidirectional power switches, today announced that its Board of Directors (“Board”) appointed two new independent members, Drue Freeman and Greg Knight, to the Board. As a result of these appointments, Ideal Power’s Board will increase in size from three to five members, four of whom are independent. These directors will bring deep expertise in semiconductors and significant experience and relationships in the Company’s initial target markets for B-TRAN™, including electric vehicles (EVs), renewable energy, energy storage and power electronics. “Drue has spent his career in the semiconductor industry, and brings commercial and strategic expertise and...

Day: March 14, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice